These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33839101)

  • 1. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis.
    Rokkas T; Gisbert JP; Malfertheiner P; Niv Y; Gasbarrini A; Leja M; Megraud F; O'Morain C; Graham DY
    Gastroenterology; 2021 Aug; 161(2):495-507.e4. PubMed ID: 33839101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of second-line regimens for
    Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
    BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Efficacy and Safety of Regimens for Helicobacter pylori Eradication Treatment in China: A Systemic Review and Network Meta-Analysis.
    Li J; Shi H; Zhou F; Xie L; Lin R
    J Clin Gastroenterol; 2024 Jan; 58(1):12-23. PubMed ID: 38084866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication.
    Yeo YH; Hsu CC; Lee CC; Ho HJ; Lin JT; Wu MS; Liou JM; Wu CY;
    J Gastroenterol Hepatol; 2019 Jan; 34(1):59-67. PubMed ID: 30169908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Vonoprazan-based treatment of Helicobacter pylori infection: a systematic review and network meta-analysis.
    Huang S; Li B; Pang XY; Gao WW
    BMC Infect Dis; 2024 Sep; 24(1):953. PubMed ID: 39261752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line rescue treatment of
    Lin TF; Hsu PI
    World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis.
    Xin Y; Manson J; Govan L; Harbour R; Bennison J; Watson E; Wu O
    BMC Gastroenterol; 2016 Jul; 16(1):80. PubMed ID: 27460211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis.
    Wang B; Lv ZF; Wang YH; Wang H; Liu XQ; Xie Y; Zhou XJ
    World J Gastroenterol; 2014 Oct; 20(40):14973-85. PubMed ID: 25356059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of different probiotics supplements for triple helicobacter pylori eradication: a network meta-analysis.
    Wang Y; Wang X; Cao XY; Zhu HL; Miao L
    Front Cell Infect Microbiol; 2023; 13():1120789. PubMed ID: 37256113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.
    Di Caro S; Fini L; Daoud Y; Grizzi F; Gasbarrini A; De Lorenzo A; Di Renzo L; McCartney S; Bloom S
    World J Gastroenterol; 2012 Oct; 18(40):5669-78. PubMed ID: 23155306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
    Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
    Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
    Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
    Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis.
    Hsu PI; Lin PC; Graham DY
    World J Gastroenterol; 2015 Dec; 21(45):12954-62. PubMed ID: 26668516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Worldwide and Regional Efficacy Estimates of First-line Helicobacter pylori Treatments: A Systematic Review and Network Meta-Analysis.
    Zamani M; Alizadeh-Tabari S; Zamani V; Shokri-Shirvani J; Derakhshan MH
    J Clin Gastroenterol; 2022 Feb; 56(2):114-124. PubMed ID: 34855643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-day vonoprazan-based versus fourteen-day proton pump inhibitor-based therapy for first-line Helicobacter pylori eradication in China: A meta-analysis of randomized controlled trials.
    Gao W; Wang Q; Zhang X; Wang L
    Int J Immunopathol Pharmacol; 2024; 38():3946320241286866. PubMed ID: 39305222
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication.
    Ye CL; Liao GP; He S; Pan YN; Kang YB; Zhang ZY
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):443-55. PubMed ID: 24677603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological therapy used in the elimination of Helicobacter pylori infection: a review.
    Dos Santos AA; Carvalho AA
    World J Gastroenterol; 2015 Jan; 21(1):139-54. PubMed ID: 25574087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
    Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
    Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.